Phase II Trial of Pembrolizumab and XL888 in Patients with Advanced Gastrointestinal Malignancies
Summary
The purpose of this phase II trial is to study the side effects and best dose of Hsp90 inhibitor XL888 when given together with pembrolizumab in treating patients with advanced gastrointestinal cancer that has spread to other places in the body. XL888 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Giving XL888 with pembrolizumab may work better in treating patients with gastrointestinal cancer.
General Information
NCT#: NCT03095781
Study ID: IRB00087397
Trial Phase: Phase II
Trial Sponsor: Exelixis, Inc., Emory University, Merck Sharp & Dohme Corp.
Therapies Used in This Trial: XL888, Pembrolizumab